

Microglia secrete miR-146a-5p-containing exosomes to regulate neurogenesis in depression

Cuiqin Fan,¹ Ye Li,¹ Tian Lan,¹ Wenjing Wang,¹ Yifei Long,¹ and Shu Yan Yu^{1,2}

¹Department of Physiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China; ²Shandong Provincial Key Laboratory of Mental Disorders, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China

Enhancing neurogenesis within the hippocampal dentate gyrus (DG) is critical for maintaining brain development and function in many neurological diseases. However, the neural mechanisms underlying neurogenesis in depression remain unclear. Here, we show that microglia transfer a microglia-enriched microRNA, miR-146a-5p, via secreting exosomes to inhibit neurogenesis in depression. Overexpression of miR-146a-5p in hippocampal DG suppresses neurogenesis and spontaneous discharge of excitatory neurons by directly targeting Krüppel-like factor 4 (KLF4). Downregulation of miR-146a-5p expression ameliorates adult neurogenesis deficits in DG regions and depression-like behaviors in rats. Intriguingly, circular RNA ANKS1B acts as a miRNA sequester for miR-146a-5p to mediate post-transcriptional regulation of KLF4 expression. Collectively, these results indicate that miR-146a-5p can function as a critical factor regulating neurogenesis under conditions of pathological processes resulting from depression and suggest that microglial exosomes generate new crosstalk channels between glial cells and neurons.

INTRODUCTION

Depression, one of the most common psychiatric disorders, typically consists of symptoms involving anhedonia, pessimism, loss of appetite, and insomnia.¹ Understandably, these symptoms seriously affect and reduce the quality of life in these individuals. Depression is a recurrent lifelong condition with a complicated pathogenesis.² Current clinical antidepressant treatments have a poor prognosis, and newly developed drugs show a high failure rate in clinical trials.³ Therefore, the identification of new targets for the treatment of depression represents an essential area of investigation.

Results from previous studies have indicated that the pathophysiological processes of depression are closely related to neurotransmitter changes, an abnormal hypothalamic-pituitary-adrenal (HPA) axis and/or inflammation.⁴ In patients with depression, the volume of the hippocampus was found to be significantly decreased,⁵ an effect often positively correlated with the duration of depression.^{6–9} In addition, the size and density of neurons and glial cells in the dorsolateral prefrontal cortex were also decreased in depression.¹⁰ As most antidepressants work by increasing neurogenesis in the adult brain,¹¹ the identification of novel targets for the induction of neurogenesis suggest a new direction for research into therapeutic strategies for use in the treatment of depression.

Exosomes, which are a type of vesicle with a double membrane structure, can carry a variety of molecules, such as specific microRNAs, DNA, mRNA, and proteins, to recipient cells.¹² The capacity for transport of exosomes across the blood-brain barrier enables them to play a key role in cellular communication, neurogenesis, and synaptic plasticity in the central nervous system.^{13,14} A diverse array of cells, including microglia, can secrete exosomes.¹⁵ A previous study has reported that microglia participate in stem cell proliferation and survival through their release of important trophic factors and anti-inflammatory cytokines.¹⁶ In addition, it has been reported that microglia can secrete exosomes carrying miRNA that are capable of exerting an acute impact upon adult neuroplasticity.^{17,18} In this way, microglia are considered as active regulators of adult neurogenesis,¹⁹ and these microglia appear to perform this function at least by secreting exosomes to promote inter-neuronal communication.²⁰ However, to the best of our knowledge there are no reports on the impact of exosomes and their cargo as related to the development of depression.

MicroRNAs (miRNAs) are non-coding RNAs comprised of 18–24 nucleotides that regulate gene expression by directly modifying messenger RNA (mRNA) after transcription.²¹ miRNAs have been shown to be abundantly expressed in the brain, and miRNA dysfunction contributes to neurological diseases.^{22,23} For example, levels of miR-133b are decreased in the midbrain of Parkinson's disease patients.²⁴ Furthermore, of particular relevance to the present investigation, recent evidence has emerged indicating that miRNAs are important participants in the pathogenesis of depression.²⁵ Results from clinical studies have revealed that various miRNA alterations are present in cerebrospinal fluid, serum, and the ventral prefrontal cortex in patients with major depression disorder (MDD).²⁶ Thus, clarifying the mechanisms of miRNA regulation in the neurogenesis of depression, may provide new therapeutic strategies for patients with depression.

In this study, we investigated the capacity for microglial transfer of miRNA to neurons through secretion of exosomes as a possible contributing factor impacting neurogenesis in the pathology of depression.

Received 25 July 2021; accepted 3 November 2021;
<https://doi.org/10.1016/j.jmthe.2021.11.006>.

Correspondence: Shu Yan Yu, Department of Physiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China.

E-mail: shuanyu@sdu.edu.cn




Figure 1. Neurogenesis is reduced in DG regions of CUMS rats

(A) Schematic diagram of experimental design. (B and C) Rats were assessed for depression-like behaviors in the sucrose preference test (SPT) (B) and forced swim test (FST) (C) after 5 weeks of CUMS exposure. n = 23 per group. **p < 0.01 CUMS versus control. (D) Representative confocal microscopic images of immunostainings for Sox2⁺, DCX⁺, and Nestin⁺ cells in DG regions of the hippocampus. Scale bars, 50 μ m. n = 6 per group. **p < 0.01 CUMS versus control. (E) Representative post-synaptic current

(legend continued on next page)

With use of the chronic unpredictable mild stress (CUMS)-induced rat model of depression, we found that levels of miR-146a-5p in microglia-derived exosomes were markedly increased in these rats. miR-146a-5p-enriched exosomes transferred their miR-146a-5p cargo to dentate gyrus (DG)²⁷ neurons of the hippocampus, resulting in an upregulation of miR-146a-5p in DG regions and subsequent downregulation of the miR-146a-5p neurogenesis target, Krüppel-like factor 4 (KLF4). Such effects can exert a substantial impact on neurogenesis. In addition, we found that circular RNA ANKS1B could function as a sequester for miR-146a-5p to affect neurogenesis in depression.

RESULTS

Neurogenesis is reduced in the hippocampal DG of CUMS rats

We first evaluated the behavior of rats subjected to CUMS as assessed in the sucrose preference and forced swim tests (Figure 1A). After 5 weeks of CUMS exposure, the percent of sucrose consumption in the sucrose preference test was significantly reduced, and immobility times in the forced swim test were significantly increased, in these CUMS-exposed rats compared with that of the control group (Figures 1B and 1C). These results verify that this CUMS protocol effectively induced depression-like behavior in these rats. In these CUMS rats, we found a significant reduction of newly developed cells in the DG region (Figure 1D). Moreover, the amplitude and frequency of spontaneous excitatory post-synaptic current (sEPSC) were markedly decreased in DG neurons of hippocampal slices in depressed versus control rats (Figures 1E–1G). These findings suggest that neurogenesis contributes to the pathological processes of depression.

MiR-146a-5p is upregulated in serum-derived exosomes of CUMS rats

Exosomes were isolated from rat serum by ultracentrifugation and precipitation separation to determine whether they may be associated with neurogenesis in this CUMS model of depression. These vesicles possessed a double membrane structure (Figure 2A) and a median diameter of 91.28 nm (Figure 2B), characteristics which were suggestive of exosomes. In further support of this conclusion were the findings that high expressions of the exosomal marker proteins, CD63, CD81, and Alix, were present in these vesicles. Meanwhile, poor levels of GM130 and albumin, markers of Golgi apparatus and lipoproteins, respectively, were detected by western blots (Figures 2C, S1, and S2).

It had been reported that miRNAs were enriched in exosomes. As a means to identify critical miRNAs in exosomes that may be involved with the neurogenesis related to the pathology of depression, exosomes were isolated from the serum of CUMS rats and subjected to miRNA high-throughput sequencing. A heatmap showed that various miRNAs were significantly dysregulated in samples from CUMS versus control rats (Figures 2D and S3; and Table S1). We then selected miRNAs with significant changes, such as miR-146a-

5p, miR-122-5p, miR-133a-3p, miR-206-3p, miR-187-3p, and miR-1b for further analysis by quantitative polymerase chain reaction (qPCR) analysis. Levels of these miRNAs matched well with that of the high-throughput sequencing data (Figure 2E). Notably, miR-146a-5p was identified as being most closely related to signaling pathways regulating pluripotency of stem cells (Figure 2F). Therefore, miR-146a-5p was selected as the focus of our current research.

In addition to serum-derived exosomes, we verified the expression of miRNA in DG regions of the hippocampus, a key brain region for adult neurogenesis, with use of high-throughput sequencing and qPCR (Figure S4A). Interestingly, levels of miR-146a-5p were consistent with miRNA sequencing among upregulated miRNAs (Figure S4B). In addition, the presence of miR-146a-5p in CSF showed increased levels of expression in CUMS rats as compared with that in the control group (Figure S4C).


After establishing that CUMS exposure altered levels of miR-146a-5p and that miR-146a-5p was closely related with nervous system development, we next directed our efforts to the identification of potential targets for miR-146a-5p. A total of 27 miR-146a-5p regulated genes were found to be significantly correlated with nervous system development (Figure S5). One eukaryotic transcription factor, which is expressed in neuronal stem cells (NSCs) and regulates neuronal differentiation and migration in the brain, is that of KLF4.²⁸ Results from the luciferase reporter assay demonstrated that miR-146a-5p repressed reporter activity of the transcript containing the wild-type 3' UTR of KLF4, providing further evidence that miR-146a-5p can directly regulate the expression of KLF4 mRNA (Figures 2G and 2H).

Exosomes transfer microglia-derived miR-146a-5p to DG neurons and inhibit the proliferation and differentiation of NSCs

A previous study reported that miR-146a-5p is a microglia-enriched miRNA, not present in hippocampal neurons, and expressed at much lower extent in astrocytes.²⁹ Thus, miR-146a-5p appeared to be shuttling from glia-to-neuron through exosomes. PCR results confirmed that miR-146a-5p is present in cultured microglia and exosomes thereof, more abundantly under stimulation of LPS. Conversely, miR-146a-5p was undetectable in cultured hippocampal neurons, as well as expressed much lower in astrocytes than that in microglia (Figure S6). More important, there was a dramatic increase of miR-146a-5p in exosomes secreted by BV2 cells that were treated with LPS (Figure 3A). Furthermore, we have sorted and collected microglial, neuronal, and astroglial cells individually from dissociated brain tissue by flow cytometry and verified that miR-146a-5p is highly enriched in the microglia (Figure S7).

Considering that CD13 expression is an important feature of microglial exosomes, we wanted to determine whether CD13 levels are

(sEPSC) from whole-cell recordings of spontaneous excitatory activity of DG neurons in control and CUMS rats. (F–G) Cumulative fraction plots of sEPSC amplitudes (F) and frequencies (G) of DG neurons in control and CUMS rats. $n = 18$ neurons from 7 control rats and $n = 16$ neurons from 6 CUMS rats. *** $p < 0.001$ CUMS versus control. Data represent means \pm SEM. Student's t tests for comparisons between the two groups (B–D, F, and G).



(legend on next page)

changed on the surface of these exosomes in response to depression. We found that substantial increases in CD13 levels were present on the surface of serum-derived exosomes in the CUMS versus control groups of rats. In addition, increased expression levels of other microglial-exosome markers, such as MCT-1, CD14, IL-1 β , TMEM119, and CD11b, indicates that the exosomes we collected from serum are mainly of microglial origin (Figure 3B). Next, we further used CSF1R inhibitor (PLX3397) to eliminate microglial cells of rats. As expected, treatment with PLX3397 caused a significant decrease in expression of miR-146a-5p in serum-derived exosomes and DG tissues, confirming that exosomes in serum of CUMS rats were mainly derived from microglia, which may enrich miR-146a-5p (Figure S8). As microglia can transfer functional molecules to neurons via secreted exosomes,²⁰ we next labeled serum-derived exosomes with KH67 (Figure S9A). The presence of green fluorescence-positive labels observed in these DG neurons (Figures 3C and S9B) suggested that the vesicles can be taken up by cells. These results suggested that it is possible that miR-146a-5p may be delivered to neurons to affect the proliferation and differentiation of NSCs.

To investigate whether exosomes transfer miR-146a-5p to neurons to affect neurogenesis, the effect of microglia-derived exosomes containing miR-146a on neuronal proliferation and migration were then investigated *in vitro* in cultured NSCs (Figure S10A). As shown in Figures 3D–3F, the exosomes derived from BV-2 cells which were treated with LPS significantly reduced neuronal proliferation and migration of NSCs when co-culture with these NSCs. Conversely, when BV-2 cells were pretreated with GW4869, an inhibitor of vesicle formation, the decreases in neuronal proliferation (Figure S10B) and migration (Figures S10C and S10D) in NSCs were prevented, indicating an inhibition in the secretion of exosomes containing miR-146a-5p significantly increased neuronal proliferation and migration of NSCs. Moreover, we performed the lentiviral transfection experiments to knock out miR-146a-5p in BV2 cells before LPS treatment, and found that the exosomes derived from these BV2 cells have no inhibitory effect on neurogenesis (Figure S11). Taken together, these data indicate that exosomes derived from microglia can deliver miR-146a-5p to neurons to regulate neurogenesis.

MIR-146a-5p suppresses neurogenesis via the KLF4/CDKL5 pathway

An AAV-miR-146a-5p virus was constructed to overexpress miR-146a-5p within the DG of normal rats or block miR-146a-5p in

CUMS rats (Figures 4A and 4B). Two weeks after virus injection, significant amounts of green fluorescence were present in the DG region (Figure 4C) and miR-146a-5p expression at this site was significantly upregulated in normal rats or downregulated in CUMS rats (Figures S12A and S12B). While CUMS treatment decreased sucrose preferences (Figure 4D) and increased the immobility times (Figure 4E), these effects were essentially reversed following the downregulation of miR-146a-5p in these CUMS rats. In contrast, the overexpression of miR-146a-5p in normal rats resulted in the display of behavioral responses indicative of a depression-like phenotype.

The effects of these AAV-miR-146a-5p virus treatments on neurogenesis in DG neurons were also assessed. In normal rats treated with AAV-miR-146a-5p to overexpress miR-146a-5p, the number of newly developed cells were all significantly reduced (Figures 4F and S12C) as were sEPSC frequencies and amplitudes (Figures 4G–4I). Conversely, the number of new neurons and sEPSC amplitudes and frequencies were significantly increased in CUMS rats receiving AAV-miR-146a-5p-shRNA to downregulate miR-146a-5p.


We next sought to investigate some of the downstream molecular mechanisms through which miR-146a-5p may regulate DG neurogenesis. Given that miR-146a-5p directly regulates KLF4 expression, we determined the protein levels of KLF4 in the DG region of these AAV-miR-146a-5p virus-treated rats. The microinjection of miR-146a-5p in normal rats significantly decreased KLF4 and Cdk5 protein expression, while phosphorylation levels of STAT3 were notably increased (Figure 4J). This KLF4 can directly target the phosphorylated form of STAT3 (p-STAT3) and inhibit its expression,³⁰ while Cdk5 contributes to the formation of new granular neurons.³¹ Within the CUMS group, expressions of Klf4 and Cdk5 were all significantly increased, but levels of phosphorylated Stat3 were significantly decreased within DG areas following AAV-miR-146a-5p-shRNA (Figure 4K). These results demonstrate that miR-146a-5p affected neurogenesis in DG neurons via the KLF4/CDKL5 pathway.

KLF4 is necessary for neurogenesis and alleviates depression-like phenotypes in rats

To assess whether a downregulation of KLF4 contributes to the inhibition of neurogenesis as associated with the development of depression, AAV-KLF4-shRNA was injected bilaterally into the DG of normal rats (Figures 5A and 5B). A marked decrease in the protein expression of KLF4 was observed at 2 weeks after AAV-KLF4-shRNA

Figure 2. miR-146a-5p is upregulated in serum-derived exosomes of CUMS rats

(A) Representative transmission electron microscopy images of rat serum-derived exosomes. Scale bar, 200 nm. n = 6 per group. (B) Representative nanoparticle tracking analysis of exosomes derived from rat serum. n = 6 per group. (C) Representative western blot images of relative protein levels for CD63, CD81, Alix, GM130, and β -tubulin in rat serum-derived exosomes. n = 5 per group. (D) Heatmap of miRNAs expressed in exosomes derived from control and CUMS rat serum. n = 3 per group. (E) Relative expression levels of miR-146a-5p, miR-122-5p, miR-187-3p, miR-133a-3p, miR-206-3p, and miR-1b in exosomes obtained from control and CUMS rat serum. SnRNAU6 as the internal controls. Control, n = 20; CUMS, n = 18. **p < 0.01, ****p < 0.0001 CUMS-Exo versus Ctrl-Exo. (F) Bar graphs represent magnitudes of significant correlations for miR-146a-5p-mediated signaling pathways as indicated by respective p values (–log₂ scaled). (G and H) Predicted putative seed-matching sites between miR-146a-5p and KLF4 (G) and Luciferase reporter assay results as performed on 293T cells to detect relative luciferase activities of WT and MUT KLF4 reporters (H). n = 6 per group. #####p < 0.0001 WJUT + rno-miR-146a-5p versus WT + rno-miR-146a-5p, ****p < 0.0001 WT + rno-miR-146a-5p versus WT + NC. Data represent means \pm SEM. Student's t tests for comparisons between the two groups (E). One-way ANOVA with Tukey's post hoc test for multiple comparisons involving >2 groups (F). WT, wild type; MUT, mutation; NC, normal control; Ctrl, control.



(legend on next page)

injection (Figure 5C). These AAV-KLF4-shRNA injected rats displayed behavioral responses characteristic of depression as indicated by decreases in their sucrose preference and significant increases in immobility times (Figures 5D and 5E). As shown in Figure 5F, knock-down of KLF4 expression resulted in significant anti-neurogenesis effects as the number of newly developed cells within the hippocampal DG region were reduced. In addition, protein levels of Cdkl5 were significantly decreased, while phosphorylation levels of STAT3 greatly increased (Figure 5G).

CircANKS1B is decreased in the DG region of CUMS rats and regulates neurogenesis via the miR-146a-5p/KLF4 pathway

As circRNAs mainly function as miRNA “sequesters” to inhibit miRNA activity,³² we were interested in determining the key circRNAs that might be involved with regulating miR-146a-5p expression. Results obtained from the transcriptome sequencing of circRNA expression within DG regions of CUMS rat revealed that statistically significant differences in circRNA expression were present as compared with that in control rats (Figures S13A–S13C). A substantial downregulation in circANKS1B was observed in these rats (Figures S13D and S13E) and, as expected, circANKS1B bound miR-146a-5p through miRNA seed sequence matching (Figure S13F).

To follow up on these findings, we next used AAV2/5 viral vectors to knock down or overexpress circANKS1B levels within the DG region as a means to assess the role of circANKS1B in the depression (Figures S14A–S14C). The markedly increased levels of circANKS1B in rats receiving AAV-circANKS1B and decreased levels in those receiving AAV-circANKS1B-shRNA verified that a high transfection efficiency was present in the DG (Figures S14D and S14E). Within normal rats, AAV-circANKS1B-shRNA treatment increased the levels of miR-146a-5p (Figure 6A). Following knockdown of circANKS1B in the DG, protein levels of KLF4 and CDKL5 were significantly reduced, phosphorylation levels of STAT3 were notably increased (Figures 6B and S15A), while AAV-circANKS1B treatment significantly increased KLF4 and CDKL5 expression, and induced phosphorylation levels of STAT3 (Figures 6C and S15B). Accordingly, it appears that circANKS1B regulates neurogenesis within the DG by affecting the expression of miR-146a-5p. This conclusion follows from the findings that neurogenesis in the circANKS1B-shRNA-infected DG area was reduced, while the overexpression of circANKS1B in the DG of CUMS rats increased the number of newly developed cells (Figure 6D). Furthermore, as shown in Figures 6E and 6F, cir-

cANKS1B can exert corresponding effects upon regulating depression-like behaviors in rats. These results suggest that circANKS1B can function as a sequester for miR-146a-5p to regulate the translational expression of KLF4, thus participating in the neurogenesis associated with depression.

DISCUSSION


In this study, we provide the first evidence indicating that microglia-specific miR-146a-5p may be a key factor involved in depression and unravel a previously unrecognized mechanism of neurogenesis associated with depression. Our results suggest that: (1) chronic unpredictable stress induces depression-like symptoms, which are accompanied with an inhibition of hippocampal DG neurogenesis in rats, (2) exosomes derived from microglia transport miR-146a-5p to DG regions where they can then regulate neuronal function, (3) miR-146a-5p regulates the neurogenesis linked with depression through the KLF4/CDKL5 pathway, and (4) circANKS1B is involved in the development of depression via the miR-146a-5p signaling pathway. Collectively, these data offer the novel hypothesis that microglia, which secrete exosomes containing miR-146a-5p, play an important role in the neurogenesis that is coupled with depression via the miR-146a-5p/KLF4 pathway (Figure 7). miR-146a-5p may thus represent a new potential therapeutic target for depression.

Emerging findings have indicated the importance of neurogenesis in central nervous system disease and, specifically, depression is closely associated with reduced neurogenesis.⁹ Interestingly, microglial degeneration is also observed in depressed patients.³³ In this study, we established that chronic unpredictable stress effectively induces symptoms of depression in rats and, more importantly, that these behavioral responses were accompanied with alterations in neurogenesis and reductions in neuronal activity within the hippocampal DG area. miRNAs play important roles in neurogenesis and participate in the transition of NSCs from proliferation to differentiation stages.³⁴ Our current study was designed to focus upon key miRNAs that can regulate neurogenesis and their role in the pathology of depression.

The therapeutic potentials of miRNAs are gaining increasing attention of late. In fact, miRNAs have been successfully used in the treatment of cancer,³⁵ and miRNAs as therapeutic agents for depression, have shown some promising results. However, there remains much to work to be done before miRNAs can be utilized as safe and effective

Figure 3. Internalization of microglia-derived exosomes in DG neurons and effects on neuronal differentiation and migration

(A) Relative expression levels of miR-146a-5p in BV-2-derived exosomes. SnRNAU6 as the internal controls. n = 6 per group. **p < 0.01 BV-2-LPS-Exo versus BV-2-untreated-Exo. (B) Representative western blot images of relative protein levels for CD13, MCT-1, CD14, IL-1 β , TMEM119, CD11b, and CD63 in rat serum-derived exosomes. n = 6 per group. *p < 0.05 CUMS-Exo versus Ctrl-Exo. (C) Confocal microscopy images showing internalization of exosomes in DG neurons of the hippocampus. Scale bars, 10 μ m (white), 10 μ m (red). n = 6 per group. (D–F) Exosomes derived from LPS-treated BV-2 cells (LPS/Exo) or GW4869-treated BV-2 cells (GW4869/Exo) were added into the medium. Proliferation (D) and differentiation (E and F) of neuronal stem cells (NSCs) as determined *in vitro* using immunofluorescence. Scale bars, 30 μ m. n = 5 per group. **p < 0.01, ***p < 0.001, ****p < 0.0001 LPS/Exo group (exosomes from LPS-treated BV-2 cells) versus naive group (exosomes from non-LPS- and non-GW4869-treated BV-2 cells), &p < 0.05, &&p < 0.01 LPS/GW4869/Exo group (exosomes from LPS- and GW4869-treated BV-2 cells) versus LPS/Exo group (exosomes from LPS-treated BV-2 cells). Data represent means \pm SEM. Student's t tests for comparisons between the two groups (A and B). One-way ANOVA with Tukey's post hoc test for multiple comparisons involving >2 groups (D–F). Ctrl, control.



(legend on next page)

therapeutic targets for depression, especially with regard to their methods of delivery and capacity for target specificity. Exosomes, which are considered as delivery vectors, can carry specific miRNAs to cell receptors, and play a key role in the pathogenesis of central nervous system diseases.³⁶ As exosomes can cross the blood-brain barrier, they offer a means for achieving a precise delivery of miRNA to its intended central nervous system target. Therefore, given the potential significance of exosomes as related to miRNAs, in this study we assessed the expression profile of miRNAs in exosomes from rat serum. We not only found that a specific miRNA, miR-146a-4p, was closely related to signaling pathways regulating pluripotency of stem cells, but that it was also enriched and significantly increased in the exosomes of CUMS rats. Similar effects are observed in patients with MDD. Accordingly, these data provide clear evidence for the possibility that exosomes containing miR-146a-5p might mediate the development of neurogenesis in depression. As the DG of the adult brain represents a key region for neurogenesis,³⁷ our studies were focused on this site. Interestingly, miR-146a-5p was found to be markedly increased in the DG area of CUMS rats. Based on these results, we hypothesize that exosomes carrying miR-146a-5p are internalized within DG neurons, resulting in their upregulation at this site and, in this way, participate in the neurogenesis associated with depression.

miRNAs have been shown to play important roles in both brain development and regulation of adult neuronal cell functions.³⁸ Interestingly, the brain has a particularly high proportion of tissue-specific and tissue-enriched miRNAs.^{39–42} Neuronal miRNA expression represents a highly specific cell-type process, such as neuronal-enriched miR-376a and astrocyte-enriched miR-21.⁴³ Of particular significance to the present investigation, miR-146a-5p has been shown to be a microglial-enriched miRNA that affects excitatory synapses.^{17,18} Therefore, we postulated that the increased levels of miR-146a-5p found in exosomes of CUMS rats were secreted by microglia. Amino-peptidase CD13 is an important characteristic protein of exosomes derived from microglia,⁴⁴ and high expression of CD13 was observed in the serum-derived exosomes of depressed rats, providing support for this hypothesis. Meanwhile, the increased expression of some other specific markers of microglial exosomes, such as MCT-1, CD14, IL-1 β , TMEM119, and CD11b, further confirmed that the exosomes in serum of CUMS rats are main of microglial origin.


It has been reported that glial-enriched miR-146a-5p can inhibit neuronal differentiation.²⁹ Consistent with previous studies, we found that exosomes containing 146a-5p as secreted by microglia inhibited neuronal differentiation and migration of NSCs. Furthermore, miR-146a-5p suppresses neurogenesis in the DG region of the hippocampus, thereby enhancing depression-like behaviors. However, details regarding molecular mechanisms through which miR-146a-5p regulates neurogenesis in the DG region require further investigation.

A single miRNA can target hundreds of mRNAs to regulate a variety of pathophysiological processes.^{45,46} As one example, miR-124 can regulate neurogenesis by targeting Dlx2⁴⁷ and Sp1 to regulate the differentiation of mesenchymal stem cells.⁴⁸ It has been reported that the expression of KLF4 in neural stem cells can regulate the differentiation and migration of neurons in the developing cerebral cortex.²⁸ Here, we demonstrate that KLF4 does, in fact, interact with miR-146a-5p, effects corroborated from results as obtained with *in vivo* experiments. KLF4 can specifically bind to the phosphorylated forms of STAT3 (p-STAT3) and inhibit its expression.³⁰ In addition, cyclin-dependent kinase-like 5 (CDKL5) is highly expressed in the brain and deficiencies in CDKL5 inhibit the formation of new granular neurons.³¹ In this study, miR-146a-5p appears to bind with KLF4 to inhibit the expression of CDKL5 and increase STAT3 phosphorylation levels, thereby reducing neurogenesis and inducing depression-like behaviors. KLF4 silencing induces depression-like behaviors and, consistent with previous studies, induces deficiencies in the development of new neurons. Taken together, these data demonstrate that miR-146a-5p derived from microglia-generated exosomes appears to provide a bridge between stress exposure and neurogenesis. More specifically, linking of the KLF4/P-STAT3/CDKL5 pathway, as regulated by miR-146a-5p, appears to be a key factor in the pathogenesis of depression. Whether or not miR-146a-5p regulates the expression of other genes that participate in neurogenesis remains to be determined.

circRNAs are a group of non-coding RNA molecules.⁴⁹ Recently, circRNAs were observed to be highly expressed in neurons and have been associated with neuronal development and synaptic plasticity.⁵⁰ Of particular relevance to our study is the report that abnormal expressions of circRNAs are present in the blood of

Figure 4. MiR-146a-5p in DG regions is associated with depression-like phenotypes and suppression of neurogenesis via the KLF4/CDKL5 pathway

(A) Schematics of AAV vectors engineered to overexpress miR-146a-5p or knockdown miR-146a-5p and their corresponding controls. (B) Experimental paradigm for determining behavioral responses of rats infected with the virus. (C) Illustration of viral infusion into the rat DG regions. Scale bars, 2 mm (red), 20 μ m (white). (D and E) Behavioral effects of expressing various viral constructs in DG regions as shown for the sucrose preference test (SPT) (D) and forced swim test (FST) (E). n = 18 per group. *p < 0.05, **p < 0.01 WT/AAV-miR-146a-5p versus WT/AAV-Ctrl, [#]p < 0.05, [&]p < 0.01 CUMS/AAV-miR-146a-5pi versus CUMS/AAV-Ctrl. (F) Representative confocal microscopic images of immunostainings for DCX⁺ and Nestin⁺ cells in the DG regions. Scale bars, 50 μ m. n = 6 per group. *p < 0.05, **p < 0.01 WT/AAV-miR-146a-5p versus WT/AAV-Ctrl, [#]p < 0.05 CUMS/AAV-miR-146a-5pi versus CUMS/AAV-Ctrl. (G) Representative traces of sEPSC in DG neurons of rats infected with the virus. (H and I) Cumulative fraction plots of sEPSC amplitudes (H) and frequencies (I) in neurons of rat DG regions. n = 16 neurons from 6 WT/AAV-Ctrl rats, n = 16 neurons from 7 WT/AAV-miR-146a-5p rats, n = 18 neurons from 6 CUMS/AAV-Ctrl rats, and n = 18 neurons from 6 CUMS/AAV-miR-146a-5pi rats. **p < 0.01 WT/AAV-miR-146a-5p versus WT/AAV-Ctrl, [#]p < 0.05, [&]p < 0.01 CUMS/AAV-miR-146a-5pi versus CUMS/AAV-Ctrl. (J) Representative western blot images showing relative protein levels of KLF4 and CDKL5, and phosphorylation of STAT3 in AAV-miR-146a-5p-infected DGs of WT rats. n = 6 per group. *p < 0.05 WT/AAV-miR-146a-5p versus WT/AAV-Ctrl. (K) Representative western blot images showing relative protein levels of KLF4 and CDKL5, and phosphorylation of STAT3 in AAV-miR-146a-5pi-infected DGs of CUMS rats. n = 6 per group. [#]p < 0.05 CUMS/AAV-miR-146a-5pi versus CUMS/AAV-Ctrl rat. Data represent means \pm SEM. One-way ANOVA with Tukey's post hoc test for multiple comparisons involving >2 groups (D–F, H–K). Ctrl, control.



(legend on next page)

MDD patients.⁵¹ Therefore, we used high-throughput sequencing to establish that circRNAs are involved in MDD. We also observed that circAnka1b, as an exonic circular RNA, was notably decreased in the DG region of CUMS rats. It is well known that miRNAs play a key role in post-transcriptional regulation and circRNAs function as miRNA sponges to modulate the pathogenesis and progression of various diseases.^{32,52} For example, a circRNA derived from the Sry transcript sequesters miR-138 in the testes,⁵³ while circRNA Cdr1binds miR-7 and miR-671 to regulate synaptic transmission.⁵² We speculated that circANKS1B might competitively bind with miR-146a-5p to relieve its inhibitory effects on associated target genes. Results as obtained in *in vivo* experiments have verified that circANKS1B binds to miR-146a-5p to reverse reductions in KLF4 protein. Moreover, silencing circANKS1B significantly attenuated neurogenesis and induced depression-like symptoms in normal rats, while an overexpression of circANKS1B enhanced DG neurogenesis and ameliorated depression-like behaviors in CUMS rats. In this way, we present the first evidence identifying a function for circANKS1B in the regulation of neurogenesis and behavior in rats with chronic stress, via the capacity for circANKS1B to function as an absorbing agent. However, details regarding information on the mechanisms and functional roles of circRNAs in neurological diseases, which will be needed for the development of novel candidate drugs for disease treatments, will require further investigation.

It should be pointed out that this study mainly investigated whether microglia-derived miR-146a-5p-containing exosomes can function as a critical factor to regulate neurogenesis in depression and suggests that microglial exosomes act as a new crosstalk channel between glial cells and neurons. However, there are still some limitations. Firstly, the present study lacks definitive proof to confirm the glia-to-neuron shuttling of bioactive miR-146a-5p via exosomes. Despite recent advances in exosome research, how to deliver the cargo of extracellular vesicles⁴⁰ to target cells remains largely unclear. Secondly, this study demonstrated that miR-146a-5p was mainly derived from exosomes released by microglia, and overexpressing miR-146a-5p could down-regulate the expression level of KLF4. However, whether the decreased KLF4 in the depression model is mediated by miR-146a-5p from microglia-derived exosomes needs further confirmation. In addition, chronic social stress has been shown to induce glucocorticoid-mediated pro-inflammatory response and pyramidal dendrite retraction in the hippocampus.⁵⁴ However, there are differences in function and mechanisms between the LPS-induced inflammation *in vitro* and chronic stress-induced inflammation *in vivo*. So, further study remains to clarify whether LPS stimulation could functionally

regulate neurogenesis via the HPA axis. In addition, a miRNA usually has hundreds of target genes, and previous studies have reported that IRAK1 and TRAF6 are also the most highly conserved targets of miR-146a-5p.^{55,56} Therefore, it is interesting to further investigate the comprehensive mechanisms of miR-146a-5p in depression.

In conclusion, the findings presented in this report represent the first evidence showing that miR-146a-5p is involved in the crosstalk between microglial exosomes and neurogenesis in depression. miR-146a-5p, which is enriched in microglia-derived exosomes, is shuttled to DG neurons, leading to an inhibition of neurogenesis by affecting the target gene, KLF4. In addition, we demonstrate that circANKS1B mediates miR-146a-5p regulation of KLF4 mRNA expression and its functional involvement in the neurogenesis of depression. In this way, our results reveal that microglia-derived miR-146a-5p can function as a crucial signaling mediator during neurogenesis in depression and indicate a novel role for miR-146a-5p as a therapeutic target in depression. Taken together, these observations suggest that targeting the neurogenesis involved with depression may provide a new avenue for the development of novel therapeutic strategies in the treatment of depression.

MATERIALS AND METHODS

Animals

Male Wistar rats (120–140 g) were purchased from the animal center of Shandong University. All experimental procedures were reviewed and approved by the Ethics Committee of Shandong College (ECSBMSSDU2020-2-017), and strictly abide by the International Guiding Principles of Animal Research formulated by the Council of the International Medical Science Organization. Additional information regarding the care and maintenance of these rats is contained in the [supplemental information](#).

CUMS model


Details regarding procedures for inducing the CUMS-induced rat model of depression have been described previously with slight modifications.⁵⁷ In brief, after 7 days of adaption to the laboratory conditions, rats were exposed to a variable sequence of stressors in a random sequence for 5 weeks. Descriptions of the types of stressors applied in this study and behavioral tests used to assess depression are contained in the [supplemental information](#).

Stereotaxic injection of the adeno-associated virus

The adeno-associated virus (AAV) virus used for stereotaxic injections was obtained from GENEchem (Shanghai, China). For viral

Figure 5. Blocking KLF4 in DG regions induces depression-like behaviors in normal rats and inhibits neurogenesis through the P-STAT3/CDKL5 pathway

(A) Schematics of AAV vectors engineered to knock down KLF4 and their corresponding controls. (B) Experimental paradigm for determining behavioral responses of rats infected with the virus and BrdU. (C) Representative western blot images showing the knockdown efficiency of KLF4. $n = 6$ per group. $**p < 0.01$ WT/AAV-KLF4-shRNA versus WT/AAV-Ctrl rats. (D and E) Behavioral responses in the SPT (D) and FST (E) of rats with knockdown of viral AAV-KLF4-shRNA in the DG regions. $n = 16$ per group. $*p < 0.05$, $**p < 0.01$ WT/AAV-KLF4-shRNA versus WT/AAV-Ctrl rats. (F) Representative confocal microscopic images of immunostainings for cell numbers of BrdU⁺, BrdU⁺/DCX⁺, and BrdU⁺/NeuN⁺ in the DG. Scale bars, 50 μm . $n = 6$ per group. $*p < 0.05$ WT/AAV-KLF4-shRNA versus WT/AAV-Ctrl rats. (G) Representative western blot images showing relative protein levels of CDKL5 and phosphorylation of STAT3 in virus-infected DGs. $n = 6$ per group. $*p < 0.05$, $**p < 0.01$ WT/AAV-KLF4-shRNA versus WT/AAV-Ctrl rats. Data represent means \pm SEM. One-way ANOVA with Tukey's post hoc test for multiple comparisons involving >2 groups (C–G). WT, wild type; Ctrl, control.



(legend on next page)




Figure 7. Stress-triggered microglia secrete exosomes containing miR-146a-5p to regulate neurogenesis via the miR-146a-5p/KLF4 signaling pathway in depression

ANKS1B, circRNA-ANKS1B; NSC, neural stem cell.

injection, rats were anesthetized with 2.5% isoflurane and then placed in a stereotaxic frame. Purified and concentrated AAV virus ($\sim 10^{12}$ infection units per mL) was injected bilaterally in a volume of 2.0–2.5 μL into the hippocampal DG region using an electric microinjection pump (Stoelting, USA) at a rate of 150 nL/min. The site of viral injections was verified according to the Rat Brain Atlas for Wistar rats using the following coordinates: from the bregma, -3.24 mm; medial/lateral, ± 1.7 mm; dorsal/ventral, -3.5 mm. Behavioral experiments or biochemical assays were performed at a minimum of 14 days after surgery. Injection sites were verified after behavioral tests and only data from rats with correct injection site placements were used for subsequent experiments.

Hippocampal slice preparations and electrophysiological recordings

Hippocampal slices (400 μm thick) were prepared according to procedures described previously.⁵⁸ In brief, coronal slices were sectioned using a vibratome (VT-1000, Leica) in oxygenated ice-cold cutting solution. Slices were then transferred as quickly as possible to a recovery solution for 30 min at 30°C. The slices were allowed a minimum recovery period of 1 h at room temperature

before recording. Whole-cell patch-clamp recordings were performed in DG granule cells. The glass micropipettes (4–6 M Ω) were filled with an internal solution. During recordings, slices were continuously perfused with an artificial cerebral spinal fluid at a temperature of 31°C–33°C and flow rate of ~ 2 mL/min. Cells were visualized with infrared optics on an upright microscope (BX51WI, Olympus). A MultiClamp 700B amplifier and pCLAMP10 software were used to record the electrophysiological responses (Axon Instruments). sEPSCs were recorded at a holding potential of -70 mV with 50 μM picrotoxin in the ASCF. Results were analyzed using a Mini Analysis Program and all the chemicals used in these electrophysiological recordings were purchased from Sigma. Additional details regarding these solutions are contained in the [supplemental information](#).

Additional assays/procedures

Immunofluorescence, western blotting, cell cultures, dual luciferase assay, lentivirus transfection, flow cytometry, exosome labeling, and quantitative real-time PCR were performed as described detail in the [supplemental information](#). The accession number of the RNA-seq data reported in this paper is GEO: GSE185777.

Figure 6. circANKS1B regulates neurogenesis in the DG region through the miR-146a-5p/KLF4 pathway

(A) Relative expression levels of miR-146a-5p in DG regions infected with the AAV-circANKS1B-shRNA or the AAV-circANKS1B virus. $n = 6$ per group. **** $p < 0.0001$ WT/AAV-circANKS1Bi versus WT/AAV-Ctrl, $\&\&p < 0.01$ CUMS/AAV-circANKS1B versus CUMS/AAV-Ctrl. (B and C) Representative western blot images showing relative protein levels of KLF4 in DG regions infected with the AAV-circANKS1B-shRNA (B) or the AAV-circANKS1B (C) virus. $n = 6$ per group. * $p < 0.05$ WT/AAV-circANKS1Bi versus WT/AAV-Ctrl, $\&\&p < 0.01$ CUMS/AAV-circANKS1B versus CUMS/AAV-Ctrl. (D) Representative confocal microscopic images of immunostainings for DCX⁺, Sox2⁺, and Nestin⁺ cells in DG regions infected with the virus. Scale bars, 50 μm . $n = 6$ per group. ** $p < 0.01$ WT/AAV-circANKS1Bi versus WT/AAV-Ctrl, $\&p < 0.05$, $\&\&p < 0.01$ CUMS/AAV-circANKS1B versus CUMS/AAV-Ctrl. (E and F) Behavioral responses in the SPT (E) and FST (F) of rats with expression of the AAV-circANKS1B-shRNA construct in the DG of WT rats and the AAV-circANKS1B construct in the DG of CUMS rats. $n = 18$ per group. * $p < 0.05$, ** $p < 0.01$ WT/AAV-circANKS1Bi versus WT/AAV-Ctrl, $\&p < 0.05$, $\&\&p < 0.01$ CUMS/AAV-circANKS1B versus CUMS/AAV-Ctrl. Data represent means \pm SEM. One-way ANOVA with Tukey's post hoc test for multiple comparisons involving > 2 groups (A–F). WT, wild type; Ctrl, control.

Statistical analysis

All data are expressed as the means \pm SEM and analyses performed with GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA, USA) for statistical analysis. Student's *t* tests were employed for comparisons between two groups, while a one-way analysis of variance⁵⁹ was used to establish differences among >2 groups with the Tukey's test for post hoc comparisons. Normality between group samples were assessed using the D'Agostino and Pearson omnibus normality test and Brown-Forsythe tests. When normality between sample groups was achieved, one-way ANOVA (followed by Bonferroni's multiple comparisons test), or Student's *t* test were used. Where normality of samples failed, Kruskal-Wallis one-way ANOVA (followed by Dunn's correction), or Mann-Whitney test were performed. All statistical tests were two-tailed and a $p < 0.05$ was required for results to be considered as statistically significant.

DATA AVAILABILITY

The data that support the findings of this study are available from the corresponding author upon reasonable request.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.ymthe.2021.11.006>.

ACKNOWLEDGMENTS

This study was supported by grants to S.Y.Y. from the National Natural Science Foundation of China (NSFC81873796; 82071513), the Natural Science Foundation of Shandong Province of China (ZR2020ZD25), and the Fundamental Research Funds of Shandong University (2018JC008). We thank Translational Medicine Core Facility of Shandong University for consultation and instrument availability that supported this work.

AUTHOR CONTRIBUTIONS

C.F. designed and conducted *in vivo* experiments, performed data analysis, and assisted in writing the manuscript. Y.L. performed and analyzed the electrophysiological experiments. T.L. and W.W. prepared the rat model of depression. Y.L. conducted *in vitro* experiments. S.Y.Y. designed and directed the experiments, wrote the manuscript, and approved the final version of the manuscript for publication.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

- Malhi, G.S., Coulston, C.M., Fritz, K., Lampe, L., Bargh, D.M., Ablett, M., Lyndon, B., Sapsford, R., Theodoros, M., Woolfall, D., et al. (2014). Unlocking the diagnosis of depression in primary care: which key symptoms are GPs using to determine diagnosis and severity? *Aust. N. J. Psychiatry* 48, 542–547.
- Malhi, G.S., and Mann, J.J. (2018). Depression. *Lancet* 392, 2299–2312.
- Wong, C.H., Siah, K.W., and Lo, A.W. (2019). Estimation of clinical trial success rates and related parameters. *Biostatistics* 20, 366.
- Willner, P. (2005). Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. *Neuropsychobiology* 52, 90–110.
- Schmaal, L., Hibar, D.P., Samann, P.G., Hall, G.B., Baune, B.T., Jahanshad, N., Cheung, J.W., van Erp, T.G.M., Bos, D., Ikram, M.A., et al. (2017). Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. *Mol. Psychiatry* 22, 900–909.
- Kempton, M.J., Salvador, Z., Munafo, M.R., Geddes, J.R., Simmons, A., Frangou, S., and Williams, S.C.R. (2011). Structural neuroimaging studies in major depressive disorder meta-analysis and comparison with bipolar disorder. *Arch. Gen. Psychiatry* 68, 675–690.
- Boldrini, M., Fulmore, C.A., Tartt, A.N., Simeon, L.R., Pavlova, I., Poposka, V., Rosoklija, G.B., Stankov, A., Arango, V., Dwork, A.J., et al. (2018). Human hippocampal neurogenesis persists throughout aging. *Cell Stem Cell* 22, 589.
- Cole, J., Costafreda, S.G., McGuffin, P., and Fu, C.H.Y. (2011). Hippocampal atrophy in first episode depression: a meta-analysis of magnetic resonance imaging studies. *J. Affect Disord.* 134, 483–487.
- Boldrini, M., Santiago, A.N., Hen, R., Dwork, A.J., Rosoklija, G.B., Tamir, H., Arango, V., and Mann, J.J. (2013). Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression. *Neuropsychopharmacology* 38, 1068–1077.
- Fossati, P., and Boyer, P. (2004). Relevance of neuroplasticity and cellular resilience in bipolar disorder and depression: evidence from neuroimaging and cognitive studies. *Eur. Neuropsychopharm.* 14, S123.
- Willner, P., Scheel-Kruger, J., and Belzung, C. (2013). The neurobiology of depression and antidepressant action. *Neurosci. Biobehav. Rev.* 37, 2331–2371.
- Saadatpour, L., Fadaee, E., Fadaei, S., Mansour, R.N., Mohammadi, M., Mousavi, S.M., Goodarzi, M., Verdi, J., and Mirzaei, H. (2016). Glioblastoma: exosome and microRNA as novel diagnosis biomarkers. *Cancer Gene Ther.* 23, 415–418.
- Fruhbeis, C., Frohlich, D., and Kramer-Albers, E.M. (2012). Emerging roles of exosomes in neuron-glia communication. *Front Physiol.* 3, 119.
- Xu, B., Zhang, Y., Du, X.F., Li, J., Zi, H.X., Bu, J.W., Yan, Y., Han, H., and Du, J.L. (2017). Neurons secrete miR-132-containing exosomes to regulate brain vascular integrity. *Cell Res.* 27, 882–897.
- Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J., and Lotvall, J.O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* 9, 654–U672.
- Cope, E.C., and Gould, E. (2019). Adult neurogenesis, glia, and the extracellular matrix. *Cell Stem Cell* 24, 690–705.
- McNeill, E., and Van Vactor, D. (2012). MicroRNAs shape the neuronal landscape. *Neuron* 75, 363–379.
- Prada, I., Gabrielli, M., Turola, E., Iorio, A., D'Arrigo, G., Parolisi, R., De Luca, M., Pacifici, M., Bastoni, M., Lombardi, M., et al. (2018). Glia-to-neuron transfer of miRNAs via extracellular vesicles: a new mechanism underlying inflammation-induced synaptic alterations. *Acta Neuropathol.* 135, 529–550.
- Sierra, A., Encinas, J.M., Deudero, J.J.P., Chancey, J.H., Enikolopov, G., Overstreet-Wadiche, L.S., Tsirka, S.E., and Maletic-Savatic, M. (2010). Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. *Cell Stem Cell* 7, 483–495.
- Budnik, V., Ruiz-Canada, C., and Wendler, F. (2016). Extracellular vesicles round off communication in the nervous system. *Nat. Rev. Neurosci.* 17, 160–172.
- Nowak, J.S., and Michlewski, G. (2013). miRNAs in development and pathogenesis of the nervous system. *Biochem. Soc. Trans.* 41, 815–820.
- Long, J.M., Ray, B., and Lahiri, D.K. (2012). MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. *J. Biol. Chem.* 287, 31298–31310.
- Long, J.M., Ray, B., and Lahiri, D.K. (2014). MicroRNA-339-5p down-regulates protein expression of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. *J. Biol. Chem.* 289, 5184–5198.
- Cao, D.D., Li, L., and Chan, W.Y. (2016). MicroRNAs: key regulators in the central nervous system and their implication in neurological diseases. *Int. J. Mol. Sci.* 17, 842.

25. Xiao, Y., Guan, J.X., Ping, Y.Y., Xu, C.H., Huang, T., Zhao, H.Y., Fan, H.H., Li, Y.Q., Lv, Y.L., Zhao, T.T., et al. (2012). Prioritizing cancer-related key miRNA-target interactions by integrative genomics. *Nucleic Acids Res.* *40*, 7653–7665.
26. Lopez, J.P., Fiori, L.M., Cruceanu, C., Lin, R., Labonte, B., Cates, H.M., Heller, E.A., Vialou, V., Ku, S.M., Gerald, C., et al. (2017). MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. *Nat. Commun.* *8*, 15497.
27. Lucanic, M., Plummer, W.T., Chen, E., Harke, J., Foulger, A.C., Onken, B., Coleman-Hulbert, A.L., Dumas, K.J., Guo, S.Z., Johnson, E., et al. (2017). Impact of genetic background and experimental reproducibility on identifying chemical compounds with robust longevity effects. *Nat. Commun.* *8*, 14256.
28. Cui, D.M., Zeng, T., Ren, J., Wang, K., Jin, Y., Zhou, L., and Gao, L. (2017). KLF4 knockdown attenuates TBI-induced neuronal damage through p53 and JAK-STAT3 signaling. *CNS Neurosci. Ther.* *23*, 106–118.
29. Jovicic, A., Roshan, R., Moiso, N., Pradervand, S., Moser, R., Pillai, B., and Luthi-Carter, R. (2013). Comprehensive expression analyses of neural cell-type-specific miRNAs identify new determinants of the specification and maintenance of neuronal phenotypes. *J. Neurosci.* *33*, 5127–5137.
30. Gu, H., Li, Q.D., Huang, S., Lu, W.G., Cheng, F.Y., Gao, P., Wang, C., Miao, L., Mei, Y.D., and Wu, M.A. (2015). Mitochondrial E3 ligase March5 maintains stemness of mouse ES cells via suppression of ERK signalling. *Nat. Commun.* *6*, 7112.
31. Fuchs, C., Trazzi, S., Torricella, R., Viggiano, R., De Franceschi, M., Amendola, E., Gross, C., Calza, L., Bartesaghi, R., and Ciani, E. (2014). Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3 beta signaling. *Neurobiol. Dis.* *70*, 53–68.
32. Piwecka, M., Glazar, P., Hernandez-Miranda, L.R., Memczak, S., Wolf, S.A., Rybak-Wolf, A., Filipchuk, A., Klironomos, F., Jara, C.A.C., Fenske, P., et al. (2017). Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function. *Science* *357*, eaam8526.
33. Brites, D., and Fernandes, A. (2015). Neuroinflammation and depression: microglia activation, extracellular microvesicles and microRNA dysregulation. *Front Cell Neurosci.* *9*, 476.
34. Marangon, D., Raffaele, S., Fumagalli, M., and Lecca, D. (2019). MicroRNAs change the games in central nervous system pharmacology. *Biochem. Pharmacol.* *168*, 162–172.
35. Hayes, J., Peruzzi, P.P., and Lawler, S. (2014). MicroRNAs in cancer: biomarkers, functions and therapy. *Trends Mol. Med.* *20*, 460–469.
36. Tsilioni, I., Panagiotidou, S., and Theoharides, T.C. (2014). Exosomes in neurologic and psychiatric disorders. *Clin. Ther.* *36*, 882–888.
37. Cameron, H.A., and McKay, R.D.G. (2001). Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. *J. Comp. Neurol.* *435*, 406–417.
38. Bartel, D.P. (2009). MicroRNAs: target recognition and regulatory functions. *Cell* *136*, 215–233.
39. Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., and Tuschl, T. (2002). Identification of tissue-specific microRNAs from mouse. *Curr. Biol.* *12*, 735–739.
40. Kim, J., Krichevsky, A., Grad, Y., Hayes, G.D., Kosik, K.S., Church, G.M., and Ruvkun, G. (2004). Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. *Proc. Natl. Acad. Sci. U S A* *101*, 360–365.
41. Smirnova, L., Grafe, A., Seiler, A., Schumacher, S., Nitsch, R., and Wulczyn, F.G. (2005). Regulation of miRNA expression during neural cell specification. *Eur. J. Neurosci.* *21*, 1469–1477.
42. Sempere, L.F., Freemantle, S., Pitha-Rowe, I., Moss, E., Dmitrovsky, E., and Ambros, V. (2004). Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. *Genome Biol.* *5*, R13.
43. Jorgensen, H.F., Terry, A., Beretta, C., Pereira, C.F., Leleu, M., Chen, Z.F., Kelly, C., Merkschlagler, M., and Fisher, A.G. (2009). REST selectively represses a subset of RE1-containing neuronal genes in mouse embryonic stem cells. *Development* *136*, 715–721.
44. Potolicchio, A., Carven, G.J., Xu, X.N., Stipp, C., Riese, R.J., Stern, L.J., and Santambrogio, L. (2005). Proteomic analysis of microglia-derived exosomes: metabolic role of the aminopeptidase CD13 in neuropeptide catabolism. *J. Immunol.* *175*, 2237–2243.
45. Long, J.M., Maloney, B., Rogers, J.T., and Lahiri, D.K. (2019). Novel upregulation of amyloid-beta precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5'-untranslated region: implications in Alzheimer's disease. *Mol. Psychiatry* *24*, 345–363.
46. Hu, W.J., Wen, L., Cao, F., and Wang, Y.X. (2019). Down-regulation of Mir-107 worsens spatial memory by suppressing SYK expression and inactivating NF-KB signaling pathway. *Curr. Alzheimer Res.* *16*, 135–145.
47. Cheng, L.C., Pastrana, E., Tavazoie, M., and Doetsch, F. (2009). miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. *Nat. Neurosci.* *12*, 399–408.
48. Mondanizadeh, M., Arefian, E., Mosayebi, G., Saidijam, M., Khansarinejad, B., and Hashemi, S.M. (2015). MicroRNA-124 regulates neuronal differentiation of mesenchymal stem cells by targeting Sp1 mRNA. *J. Cell Biochem.* *116*, 943–953.
49. Kawashima, H., Numakawa, T., Kumamaru, E., Adachi, N., Mizuno, H., Ninomiya, M., Kunugi, H., and Hashido, K. (2010). Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression. *Neuroscience* *165*, 1301–1311.
50. You, X.T., Vlatkovic, I., Babic, A., Will, T., Epstein, I., Tushev, G., Akbalik, G., Wang, M.T., Glock, C., Quedenau, C., et al. (2015). Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. *Nat. Neurosci.* *18*, 603.
51. Jiang, G.J., Ma, Y., An, T., Pan, Y.Y., Mo, F.F., Zhao, D.D., Liu, Y.F., Miao, J.N., Gu, Y.J., Wang, Y.G., et al. (2017). Relationships of circular RNA with diabetes and depression. *Sci. Rep.* *7*, 7285.
52. Cheng, X.F., Zhang, L., Zhang, K., Zhang, G.Y., Hu, Y., Sun, X.J., Zhao, C.Q., Li, H., Li, Y.M., and Zhao, J. (2018). Circular RNA VMA21 protects against intervertebral disc degeneration through targeting miR-200c and X linked inhibitor-of-apoptosis protein. *Ann. Rheum. Dis.* *77*, 770–779.
53. Hansen, T.B., Jensen, T.I., Clausen, B.H., Bramsen, J.B., Finsen, B., Damgaard, C.K., and Kjems, J. (2013). Natural RNA circles function as efficient microRNA sponges. *Nature* *495*, 384–388.
54. Frodl, T., and Amico, F. (2014). Is there an association between peripheral immune markers and structural/functional neuroimaging findings? *Prog. Neuropsychopharmacol. Biol. Psychiatry* *48*, 295–303.
55. Wu, H., Fan, H., Shou, Z., Xu, M., Chen, Q., Ai, C., Dong, Y., Liu, Y., Nan, Z., Wang, Y., et al. (2019). Extracellular vesicles containing miR-146a attenuate experimental colitis by targeting TRAF6 and IRAK1. *Int. Immunopharmacol.* *68*, 204–212.
56. Iacona, J.R., and Lutz, C.S. (2019). miR-146a-5p: expression, regulation, and functions in cancer. *Wiley Interdiscip. Rev. RNA* *10*, e1533.
57. Wang, P., Feng, Y.B., Wang, L.Y., Li, Y., Fan, C.Q., Song, Q.Q., and Yu, S.Y. (2019). Interleukin-6: its role and mechanisms in rescuing depression-like behaviors in rat models of depression. *Brain Behav. Immun.* *82*, 106–121.
58. Li, N., Cui, L., Song, G., Guo, L., Gu, H.T., Cao, H.S., Li, G.D., and Zhou, Y. (2018). Adolescent isolation interacts with DISC1 point mutation to impair adult social memory and synaptic functions in the hippocampus. *Front Cell Neurosci.* *12*, 238.
59. Alexander, R.C., Cabirac, G., Lowenkopf, T., Casanova, M.F., Kleinman, J., Wyatt, R.J., and Kirch, D.G. (1992). Search for evidence of herpes-simplex virus, type-1, or varicella-zoster virus-infection in postmortem brain-tissue from schizophrenic-patients. *Acta Psychiatry Scand.* *86*, 418–420.

YMTHE, Volume 30

Supplemental Information

**Microglia secrete miR-146a-5p-containing
exosomes to regulate neurogenesis in depression**

Cuiqin Fan, Ye Li, Tian Lan, Wenjing Wang, Yifei Long, and Shu Yan Yu

Figure. S1




Figure. S1. The expression levels of CD63 and CD81 in the exosomes derived from serum of rats. (A) Representative flow cytometry data showing the expression levels of CD63 in the exosomes. (B) Representative flow cytometry data showing the expression levels of CD81 in the exosomes.

Figure. S2




Figure. S2. Identification of exosome from the serum of rats. (A) Western blot analysis of the characteristic biomarker of exosomes, CD63 and Albumin.

Figure. S3




Figure. S3. Differentially expressed miRNA profiles in the serum-derived exosomes from control and CUMS rats. (A) Scatter plots are used to evaluate the difference in the expression of miRNAs between control and CUMS rat. The middle green line refers to no difference between the two groups. And the flank green lines represent 2.0fold changes. The miRNAs above the top green line and below the bottom green line indicate more than 2.0fold changes between two groups. (B) Differentially expressed miRNAs were displayed on a Volcano plots. The red represents the differentially expressed miRNAs with statistical significance, respectively ($P < 0.05$). Gray indicates no significant difference.

Figure. S4




Figure. S4. MiR-146a-5p is up-regulated in DG regions and Cerebrospinal fluid (CSF) of CUMS rats. (A) Heat map of the top 10 up- and down-regulated expressed miRNAs in hippocampal DG regions of Ctrl and CUMS rats. (B) Relative expression levels of miR-146a-5p, miR-122-5p, miR-133a-3p and miR-206-3p in DG tissue. Control: n=20, CUMS: n=18. **** $P < 0.0001$ CUMS vs. Ctrl. n,s, not significant. (C) Relative expression levels of miR-146a-5p in cerebrospinal fluid (CSF). n=6 per group. *** $P < 0.001$ CUMS vs. Ctrl. Data represent means \pm SEMs. Student t-tests for

comparisons between the two groups (B and C). Chronic unpredicted mild stress,
CUMS. Control, Ctrl.

Figure. S5




Figure. S5. Function annotations for target genes mediated by miR-146a-5p. (A) Bioinformatical prediction of miR-146a-5p target genes related to nervous system development. (B-C) Function annotation for miR-146a-5p targeted genes in pathways related to nervous system development. The vertical axis shows annotated functions of target genes and horizontal axes shows $-\log_2$ transformed P-values (B) and gene number of each cluster (C). (D) Scatter plots demonstrating all cluster features of P-values and gene counts.

Figure. S6






Figure. S6. MiR-146a-5p was enriched in microglia-derived exosomes but not in that from neurons. (A) Immunofluorescence staining of MAP2, Iba-1 and GFAP for identifying primary hippocampal neurons, microglia and astroglial revealed a pure culture. (B) Quantitative PCR data of miR-146a-5p in exosomes derived from cultured primary neuron, astroglia and microglia. n=6 per group. (C) Quantitative PCR data of miR-146a-5p in exosomes derived from cultured primary neuron, astroglial and microglia with LPS treatment. n=6 per group. Data represent means \pm SEMs. Exosome, Exo.

Figure. S7

A



B



C




Figure. S7. MiR-146a-5p was enriched in hippocampal microglia but not in neurons. (A-B) Representative flow cytometry plots of all Neun⁺, GFAP⁺ (A) and CD11b⁺ (B) cells from brain tissues of the hippocampus, accompanied by the quantification of the percentages of neuron, astroglial and microglia. (C) Quantitative PCR data of miR-146a-5p in neuron, astroglial and microglia taken from dissociated brain tissue. n=6 per group.

Figure. S8




Figure. S8. Microglia are eliminated with CSF1R inhibitor and presented reduced levels of miR-146a-5p. (A) Schematic of the experimental design: Wister

wild-type rats were treated with PLX3397 for 14 days to deplete microglia. (B)

Representative images from brain sections stained with anti- Iba-1 from the hippocampal region of No-PLX3397 (Left) and PLX3397 treated rat. Scale bar, 100 μ m. (C) Quantification of the number of Iba-1⁺ cells in the hippocampus

shows >90% elimination of microglia with PLX3397 treatment. n=6 per group. (D) Quantitative PCR analysis shows robust reductions in miR-146a-5p in hippocampal DG of rat treated with PLX3397. n=6 per group. (E) Quantitative PCR analysis shows

significant reductions in miR-146a-5p in exosomes derived from serum of rat treated with PLX3397. n=6 per group. **** P <0.0001 PLX3397 vs. Ctrl. &&&& P <0.0001

with PLX3397. n=6 per group. **** P <0.0001 PLX3397 vs. Ctrl. &&&& P <0.0001

PLX3397-Serum-Exo vs. Ctrl-Serum-Exo. Data represent means \pm SEMs. One-way ANOVA with Tukey's post-hoc test for multiple comparisons involving >2 groups (C-E). Control, Ctrl. Exosome, Exo.

Figure. S9




Figure. S9. Internalization of microglia-derived exosomes in DG regions. (A) Experimental paradigm for determining exosome uptake in DG neurons. (B) Confocal microscopy images showing internalization of exosomes in DG regions of SOX-2 cells and DCX cells. Scale bar: White, 10 μ m, Red, 10 μ m. n=6 per group.

Figure. S10






Figure. S10. MiR-146a-5p-containing exosomes derived from BV-2 cells inhibited the proliferation and differentiation of NSCs. (A) Confocal microscopy images showing the neural stem cells. (B-D) Exosomes derived from LPS-treated BV-2 cells (LPS/Exo) or GW4869-treated BV-2 cells (GW4869/Exo) were added into the medium. Proliferation(B) and differentiation(C-D) of NSCs in vitro detected by immunofluorescence. Scale bar, 30 μ m. n=5 per group (C), n=4 per group (B, D). ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ LPS/Exo group (exosomes from LPS treated BV-2 cells) vs. naive group (exosomes from non-LPS and non-GW4869 treated BV-2 cells), & $P < 0.05$, && $P < 0.01$ LPS/GW4869/Exo group (exosomes from LPS and GW4869 treated BV-2 cells) vs. LPS/Exo group (exosomes from LPS treated BV-2 cells). Data represent means \pm SEMs. One-way ANOVA with Tukey's post-hoc test for multiple comparisons involving >2 groups (B-C). Control, Ctrl. Exosome, Exo.

Figure. S11


A




B




C




D



E



F



G




Figure. S11. Exosomes derived from the BV-2 cells which knocking-out miR-146a-5p have no inhibitory effects on the neurogenesis. (A) Schematic representation of NSCs co-cultured with BV-2-derived exosomes. (B) Representative images of BV-2 cells transfected with Lentivirus. Scale bar, 150 μm . (C) The altered miR-146a-5p level in BV-2 cells after LV-146a-5pi transfection. n=6 per group. (D) The altered miR-146a-5p level in exosomes derived from BV-2 cells transfected with LV-146a-5pi. n=6 per group. (E-G) Proliferation (E) and differentiation (F, G) of neuronal stem cells (NSCs) as determined in vitro using immunofluorescence. Scale bar, 30 μm . n=6 per group. *** $P < 0.001$ BV-2/LV-miR-146a-5pi vs. BV-2/LV, &&& $P < 0.001$ BV-2/LV-miR-146a-5pi-Exo vs. BV-2/LV-Exo. Data represent means \pm SEMs. One-way ANOVA with Tukey's post-hoc test for multiple comparisons involving >2 groups (C-G). Exosome, Exo.

Figure. S12




Figure. S12. Estimation of expression level of viral constructs and neurogenesis through Stereotactic injection. (A) The expression level of miR-146a-5p in DG region infected with AAV-146a-5p. n=10 per group. **** $P < 0.0001$ WT/AAV-miR-146a-5p vs. WT/AAV-Ctrl. (B) The expression level of miR-146a-5p in DG region

infected with AAV-146a-5pi. n=10 per group. $P < 0.0001$ CUMS/AAV-miR-146a-5pi vs. CUMS/AAV-Ctrl. (C) Representative confocal microscopic images of immunostainings for Sox2⁺ cells in the DG regions. Scale bar, 50 μ m. n=6 per group. $*P < 0.05$ WT/AAV-miR-146a-5p vs WT/AAV-Ctrl, $^{\&}P < 0.05$ CUMS/AAV-miR-146a-5pi vs CUMS/AAV-Ctrl. Data represent means \pm SEMs. One-way ANOVA with Tukey's post-hoc test for multiple comparisons involving >2 groups (A -C). Wild type, WT. Chronic unpredicted mild stress, CUMS. Control, Ctrl.

Figure. S13




Figure. S13. Differences and characterizations in circRNA expression profiles between control and CUMS rats. (A) Differentially expressed circRNAs were displayed on a scatter plot. The middle green line refers to no difference between the two groups. And the flank green lines represent 2.0fold changes. The miRNAs above

the top green line and below the bottom green line indicate more than 2.0fold changes between two groups. (B) Differentially expressed circRNAs were displayed on a volcano plot. The red represents the differentially expressed circRNAs with statistical significance, respectively ($P < 0.05$). Gray indicates no significant difference. (C) Heat map of the top 20 differentially up- and down-expressed circRNAs between control and CUMS rats. (D) Relative expression levels of circRNAs in DG tissue. $n = 20$ per group. **** $P < 0.0001$ CUMS vs. Ctrl. (E) Comparison between circRNAs sequencing data and qPCR results were consistent with that obtained in the sequencing results. (F) Predicted putative seed-matching sites between circANKS1B and miR-146a-5p. Data represent means \pm SEMs. Student t-tests for comparisons between the two groups (D). Chronic unpredicted mild stress, CUMS. Control, Ctrl.

Figure. S14






Figure. S14. Estimation of expression level of viral constructs through

Stereotactic injection. (A) Schematics of AAV vectors engineered to overexpress circANKS1B, circANKS1B shRNA, and their corresponding controls. (B) Experimental paradigm for determining behavioral responses of rats infected with the virus. (C) Representative coronal section showing the expression of AAV-eGFP in DG regions of rats. (D) The expression level of circANKS1B in DG region infected with AAV-ANKS1Bi. n=8 per group. * $P < 0.05$ WT/AAV-circANKS1Bi vs. WT/AAV-Ctrl. (E) The expression level of circANKS1B in DG region infected with AAV-ANKS1B. n=8 per group. $P < 0.001$ CUMS/AAV-circANKS1B vs. CUMS/AAV-Ctrl. Data represent means \pm SEMs. One-way ANOVA with Tukey's post-hoc test for multiple comparisons involving >2 groups (D-E). Chronic unpredicted mild stress, CUMS. Control, Ctrl. Wild type, WT.

Figure. S15




Figure. S15. Estimation of expression level of CDKL5 and p-STAT3 through Stereotactic injection. (A) Representative western blot images showing relative protein levels of CDKL5 and Phosphorylation of STAT3 in AAV-ANKS1Bi infected DGs of WT rats. n=6 per group. * $P < 0.05$ WT/AAV-ANKS1Bi vs WT/AAV-Ctrl. (B) Representative western blot images showing relative protein levels of Cdkl5 and Phosphorylation of STAT3 in AAV-ANKS1B infected DGs of CUMS rats. n=6 per group. * $P < 0.05$ CUMS/AAV-ANKS1B vs CUMS/AAV-Ctrl rat. Data represent means \pm SEMs. One-way ANOVA with Tukey's post-hoc test for multiple comparisons involving >2 groups (A, B). Control, Ctrl.

Table S1. The top 12 up-regulated and down-regulated expressed miRNAs ranked by P-value in serum-derived exosomes produced from control and CUMS rats

miRNA ID	log2 (foldchange)	P-value	miRNA ID	log2 (foldchange)	P-value
miRNAs upregulated			miRNAs downregulated		
rno-miR-146a-5p	1.6312	0.002193	rno-miR-1-3p	-2.9663	1.04E-06
rno-miR-187-3p	2.2387	0.0041260	rno-miR-1b	-3.0321	2.57E-06
rno-miR-122-5p	2.283	0.004604	rno-miR-206-3p	-2.6015	1.28E-05
rno-miR-429	1.8147	0.0146116	rno-miR-133a-3p	-1.7835	0.001038
rno-miR-192-5p	1.7775	0.0165811	rno-miR-542-3p	-12.9304	0.001958
rno-miR-486	1.6663	0.0176033	rno-miR-133b-3p	-1.9624	0.00475
rno-miR-484	2.0131	0.0214115	rno-miR-149-5p	-1.717	0.034851
rno-miR-27a-5p	1.491	0.0214272	rno-miR-24-1-5p	-11.9792	0.038419
rno-miR-129-5p	1.8089	0.0256463	rno-miR-6329	-11.9629	0.03898
rno-miR-185-5p	1.6643	0.0335633	rno-miR-341	-11.902	0.043148
rno-miR-200b-3p	1.5095	0.0378972	rno-let-7b-3p	-12.1555	0.043672
rno-miR-191a-5p	1.1623	0.0484238	rno-miR-322-3p	-1.4519	0.047895

Table S2. Primer sequences of target genes used for quantitative real-time PCR in this study

Gene/CircRNA ID	Species	Suppliers	Product ID or Primer sequences
miR-146a-5p	Rat	GeneCopoeia	RmiRQP0196
miR-122-5p	Rat	GeneCopoeia	RmiRQP0056
miR-133a-3p	Rat	GeneCopoeia	RmiRQP0166
miR-206-3p	Rat	GeneCopoeia	RmiRQP0308
miR-1b	Rat	GeneCopoeia	RmiRQP0044
miR-187-3p	Rat	GeneCopoeia	RmiRQP0251
miR-16	Rat	GeneCopoeia	RmiRQP0227
miR-451	Rat	GeneCopoeia	RmiRQP0509
RsnRNA U6	Rat	GeneCopoeia	RmiRQP9003
Circ-ANKS1B rno_circ:chr7:307080 31-30735182	Rat	Ribobio	Forward: AAAATGGAAGCCAGAGTGTAGGA Reverse: GGGAAGTAACCTTTGTTGTCTGG
Circ-ARHGAP21 rno_circ:chr17:87795 320-87797427	Rat	Ribobio	Forward: AAGAGAATGGAAACAGAGGAGGTG Reverse: ACGATTCGTCTTCGGACGGT
Circ-PJA2 rno_circ:chr9:112023 471-112027242	Rat	Ribobio	Forward: TTGACAAAGACGAAGACAGGAATC Reverse: GCAGCGTCTATGCTTCCAGTT
Circ-SYNC rno_circ:chr5:147482 283-147483432	Rat	Ribobio	Forward: CGCTCGTGAGGCAAAAACA Reverse: TGAGTCCTGAAGAGGAAACTGG

Supplementary Methods and Materials

Animals

Male Wistar rats (120-140g) were purchased from the animal center of Shandong University (Shandong, China) and randomly settled into groups. Rats were raised in single cages and maintained on a 12 h light/dark cycle at 22-25°C with free access to food and water. All experimental procedures were reviewed and approved by the Ethics Committee of Shandong College, and strictly abide by the International Guiding Principles of Animal Research formulated by the Council of the International Medical Science Organization.

CUMS model

Rats were exposed to a variable sequence of stressors consisting of 24-h food deprivation followed by 24-h water deprivation, overnight illumination, swimming (4°C, 5 min), wet bedding (24h), tail clip (1 min), tilted cage (24h), physical restraint (2h), noise (2h) and shaking (1h). Stressors were administered daily in a random sequence for five weeks. The sucrose preference and forced swimming tests were then used to assess depression-like behaviors in these rats.

Behavioral Tests

After the five-week period of stress administration, behavioral tests for assessing depression were conducted as described previously¹. For the sucrose preference test, rats were placed individually in cages and provided with two bottles of sucrose

solution (1%, w/v) located at opposite sides of the cage at identical heights for the first 24-h period. For the second 24 h period one bottle of sucrose solution was replaced with a bottle containing tap water. Immediately after, rats were deprived of water and food for 24h. On the fourth day, sugar water consumption was measured over a 3 h period when rats were given two bottles (100 ml each) with one containing 1% sucrose in water and the other only tap water. Bottle positions were reversed after 1.5 hours. Sucrose preference was defined as $\frac{\text{sucrose consumption}}{[\text{water consumption} + \text{sucrose consumption}]} \times 100\%$ during the 3-h test.

The forced swimming test has been established as an effective method to assess depression-like behaviors in rats. The procedure for this test consists of placing the rats individually in a glass cylinder (height: 80 cm, diameter: 30 cm) filled with 40 cm of water (25°C) for 15 min on day 1. After 24 h, rats were again individually placed in the cylinder for a 5 min period and immobility and swimming times were recorded for each rat. Immobility time was defined as only exposing the head above the surface of the water while floating.

Cerebrospinal fluid (CSF) samples

CSF samples were collected as described previously with slight modifications². Rats were anesthetized with 2.5% isoflurane and placed in the stereotaxic instrument. A sagittal incision of the skin was made inferior to the occiput to expose the foramen magnum. A sterile cotton swab was then used to absorb any blood on the dura mater. A penetrating capillary tube was inserted into the cisterna magna through the dura

mater to enable CSF to flow into the capillary tube. The CSF sample was frozen on dry ice and then transferred to a -80 °C freezer.

Serum samples

A blood sample was obtained from the abdominal aorta of anesthetized rats using a 10ml syringe. The blood sample was stored at 4°C for 3-4 h, then centrifuged at 5000 rpm at 4°C for 10 min followed by centrifugation at 13000 rpm for 10 min at 4 ° C. The upper phase of serum was collected and shipped on dry ice to the RiboBio Biotechnology Company (Guangzhou, China) for exosome isolation and miRNA sequencing.

Microglia depletion

To deplete microglia in vivo, rats were treated with the CSF1R inhibitor PLX3397 (Selleck Chemicals, USA) which mixed into the standard chow. The dose and administration route were as described previously with minor modifications³. The PLX3397 was administered at 600 ppm as well as the control group received standard chow on daily for 14 days.

BV-2 cell culture

BV-2 is a clonal mouse microglia cell line with the functional and morphological characteristics of microglia⁴. The cells were purchased from Iennio (Guangzhou, China), and cultured in DMEM supplemented with 10% FBS and 1%

penicillin/streptomycin (Thermo Fisher Scientific) at 37 °C in 5% CO₂. The cells were transferred to serum-free medium and then exposed to LPS (100 ng/ml) for 24 h to isolate exosomes from cell culture supernatants.

Primary neural cell culture

Primary NSCs were isolated from P0 to P1 neonatal rats as described previously with minor modifications⁵. Briefly, the cortex and hippocampus were removed from the brain and placed in cold Dulbecco's modified Eagle's medium (DMEM) with 4.5 g/L glucose. The meninges were carefully cleared and discarded. Tissues were triturated in proliferation medium [DMEM/F12 supplemented with 1% penicillin/streptomycin (Gibco), 2% B27 supplement (Gibco), 20 ng/ml recombinant human EGF (Gibco) and 20 ng/ml recombinant human FGF2 (Gibco)] and obtain a single cell suspension. The cell suspension was filtered through a 70- μ m cell strainer (Millipore, Billerica, MA) and cells were counted using a hemocytometer, followed by plating on 6-well tissue culture plates at a density of 1000,000 cells/well and incubated at 37 °C in 5% CO₂. Cells were cultured as neurospheres in complete proliferation media and half of the medium was refreshed every 3 days.

Primary culture of mixed glial cell was prepared from newborn P1 rat pup as described previously^{6,7}. In brief, the brain of animals (P0-P1 rat) was extracted and placed into the ice-cold DMEM medium with 4.5 g/L glucose. The removal of the meninges with forceps should be carefully. Then, the brain tissue was trypsinized with 0.25% trypsin and DNase for 5-10 min at room temperature to obtain the cell

suspension through a 70- μ m cell strainer. The cells were seeded into poly-L-lysine-coated flasks with DMEM/F12 medium supplemented with 10% FBS. After in vitro culture for 10–14 days, microglia cells were isolated from mixed glial cultures by gently shaking the flasks for 30 min on an orbital shaker at 37 °C, while astrocyte was layer on the flask surface. The purity of the microglia or astroglia preparation were identified by staining with rabbit anti-Iba1 and rabbit anti-GFAP, respectively.

Primary neurons cells were isolated from P1 rat fetuses as described previously⁸⁻¹⁰. Briefly, the brains were rapidly removed and placed in the 10-cm dish with ice-cold DMEM medium with 4.5 g/L glucose. The meninges were removed and then transferred to the centrifugation tubes containing 0.25% trypsin for 5-10 min at room temperature. The dissociated cells were resuspended by DMEM/F12 (containing 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin), and then seeded into 6-well plates pre-coated with poly-D-lysine (Millipore-Sigma) at a density of 1×10^6 /well. After 4 h, the neurobasal medium (containing 2% B27 supplement (Gibco), 1% Gluta-Max (Gibco) glutamine, 100 U mL⁻¹penicillin and 100 mg mL⁻¹ streptomycin) was applied as the culture medium. Cells were grown at 37 °C in 5% CO₂ and half of the medium was refreshed every 3 days. 5 μ M of cytosine arabinoside (Ara-c, Sigma) was added at 3th day of culture to control the proliferation of non-neuronal cells. The purity of the neurons was identified by staining with rabbit anti-MAP2, a neuron biomarker.

BrdU staining of NSCs

NSCs were treated with BrdU (10 μ M) for 24 hours at 37 °C in 5% CO₂ and then fixed with 70% ethanol for 5 minutes at room time⁴. Then, the cells were pretreated with 1.5M HCl for 30 min at 37°C, the Primary antibody was anti-BrdU (1:1000, CST Technology)

Co-culture of NSCs with BV-2 -derived exosomes

To determine the impact that microglia-derived exosomes have on neurogenesis in vitro, we use a co-culture assay of 24-well plates as described previously with minor modifications^{10,11}. In brief, BV-2 cells were cultured in serum-free medium and pretreated with GW4869 (10 μ M) for 30min prior to the application of LPS (100ng/ml) for 24 hours. Before exosomal treatment, NSCs were incubated for 4 hours in poly L-lysine-coated plates and the medium were changed to fresh proliferation media (for the proliferation study), or differentiation media (Neurobasal-A media, 2%B27, and 1x penicillin/streptomycin, Invitrogen, for the differentiation study). The collected exosomes derived from BV-2 cell supernatant were added into the medium of NSCs.

Lentivirus transfection

The recombinant lentivirus (LV) used to knock-out miR-146a-5p was purchased from GENEchem (Shanghai, China), and transfected into BV-2 cells according to the manufacturer's instructions. The expression levels of miR-146a-5p were detected by qPCR analysis after 72 h.

Flow cytometry

Multiple Cell Types retrieved from rat hippocampal tissue was performed as described previously with minor modifications¹²⁻¹⁴. Briefly, rats were anesthetized and perfused with PBS solution to eliminate blood contamination from brains. Hippocampal tissue from rat brain were dissected. Enzymatic digestion was performed with Neural Tissue Dissociation Kit (P) (Miltenyi Biotec) according to manufacturer protocol. Dissociated cells were re-suspended in PBS buffer with 0.5% BSA, following by through a 70 µm cell strainer to remove any undigested tissue chunk.

The cell pellet consisting of a mixture of all brain cells was further subjected to magnetic cells sorting for microglia enrichment using CD11b/c microbeads (Miltenyi Biotec) according to manufacturer protocol. Microglia, astroglial and neurons were positively selected from cell suspensions using anti-CD11b, anti-GFAP, and anti-NeuN antibody. Samples were analyzed with the FACS Aria III flow cytometer (BD Biosciences, San Jose, CA, USA). Subsequent data analysis was performed with FlowJo software v.7.6.1 (Ashland, OR, USA).

Exosome isolation and identification

Rat serum and cell culture supernatants were collected and exosomes purified following a sequence of several centrifugation and filtration procedures as described previously¹⁵. Briefly, for serum, 2 ml of dilute serum with an equal volume of PBS were centrifuged for 30 min at 2000g. The supernatant was then centrifuged at

12000g for 45 min and 110000g for 2 h. Pellets were re-suspended in 1 ml PBS, followed by filtration through a 0.22-um filter to eliminate cellular debris. For purification of exosomes, the supernatant was ultra-centrifuged at 110000g for 70 min, followed by a wash of the exosomes pellet with 1 ml PBS and another centrifugation at 110000g for 70 min. Cell culture supernatants were centrifuged at 300g for 10 min, 2,000g for 10 min and 10,000g for 30 min to remove extraneous cells, dead cells and cellular debris. Next, the supernatant was filtered through a 0.22µm filter (Millipore-Sigma) to remove dead cells and particles larger than 200nm. Exosomes were subsequently isolated from the supernatant by centrifugation at 100,000g for 70 min. The pellet was re-suspended with PBS and centrifuged at 100000g for 70 min (Ultracentrifuge, Beckman Coulter, XPN-100). The exosome pellet was then re-suspended in 100ul PBS and stored at -80 °C.

For exosomes identification, protein levels of serum-derived exosomes were measured with use of the BCA protein assay (Thermo Scientific, MA). Equal volumes of Exosomes (10ul) were run on 10% SDS-PAGE gels and transferred to PVDF membranes. The antibodies included anti-CD63 (1:200, Santa Cruz Biotechnology), anti-CD13 (1:200, Santa Cruz Biotechnology), anti-CD14 (1:200, Santa Cruz Biotechnology), anti-Alix(1:200, Santa Cruz Biotechnology), anti-CD81 (1:500, Abcam), anti-GM130 (1:200, Santa Cruz Biotechnology), anti-Albumin (1:5000, proteintech), anti-TMEM119 (1:500, ABclonal), anti-MCT1 (1:500, Bioss), anti-IL-1β (1:1000, Abcam), anti-CD-11b (1:1000, Abcam) and anti-β-tubulin (1:1000, Cell Signaling Technology). Membranes were incubated with anti-HRP secondary

antibodies (1:5000, Bioworld) and detected with use of an ECL kit (Thermo Scientific, MA). Protein band intensities were quantified with use of Image-J software and normalized to CD63.

Exosomes were analyzed using electron microscopy as described previously with slight modifications^{10,15}. In short, a drop of freshly purified exosomes were deposited onto a paraffin membrane and covered with a 200-mesh copper mesh for 20 min. After washing with PBS, the copper mesh was fixed in 1% glutaraldehyde for 5 minutes and positively stained with uranyl acetate for 5 min, followed by methyl cellulose-uranyl acetate for 10 min. Remove excess liquid gently by using an absorbing paper and let it air dry for 5 min. Images of exosomes were obtained using a JEM-1011 electron microscope (JEOL, Japan) at an accelerating voltage of 80 kV.

Exosomes were re-suspended within 1 ml of filtered PBS and stored on ice. Exosome sizes were determined using a ZETASIZER Nano series-Nano-ZS (Malvern, England). The exosomal markers, CD63 and CD81, were analyzed using antibodies (CD63-Antibody-FITC BD 557288, CD81-Antibody-PE BD 555676) with a BD Accuri C6 flow cytometer.

Exosome labeling

Freshly isolated exosomes were labeled using the PKH67 Green Fluorescent Cell Linker Kit (Sigma-Aldrich, USA) with minor modifications of the manufacturers' instructions. Exosomes were re-suspended in 100ul Sterile PBS and added to 300ul Diluent C. This mixture was then added to 4ul of PKH67 and incubated for 4 min in

the dark. Finally, 300ul of 1% BSA solution was added to stop the reaction, followed by filtration through a 0.22- μ m filter to remove excess dye. The labeled exosomes were purified using the SBI, EXOQ5A-1 kit, and the exosome pellet was diluted in 20ul PBS for use in exosome uptake experiments. Rats were injected bilaterally with 2.0 - 2.5 μ l of purified and concentrated exosomes and brain sections were collected 4 h after exosome injection.

Exosome miRNA sequencing

Exosome miRNA sequencing determinations were performed by the RiboBio Biotechnology Company (Guangzhou, China). Exosomal RNA was isolated by using the HiPure Liquid miRNA Kit/HiPure Serum/Plasma miRNA Kit (Megan, China). The Qubit®2.0 (Life Technologies, USA) and Agilent 2200 TapeStation (Agilent Technologies, USA) were individually used to assess the quantity and integrity of Exosomal RNA yield. Exosomal RNA of each sample (50ng) was used to prepare small RNA libraries by NEBNext® Multiplex Small RNA Library Prep Set for Illumina (NEB, USA) according to the manufacturers' instructions. The libraries were sequenced using HiSeq 2500 (Illumina, USA) with a single-end 50 bp.

Tissue transcriptome sequencing

Total RNA was isolated from tissues using the Trizol kit (Invitrogen) according to the manufacturers' instructions. RNA integrity (RIN) was accessed with use of Agilent 2200 TapeStation (Agilent Technologies, USA). Purified library products were

evaluated using the Agilent 2200 TapeStation and Qubit®2.0 (Life Technologies, USA) and then sequenced using the HiSeq 2500 and HiSeq 3000 (Illumina, USA) platform at the RiboBio Company (Guangzhou, China).

Dual luciferase assay

We designed a dual luciferase assay to assess the binding of miR-146a-5p to its target gene, KLF4. The experimental plasmid was constructed by OBIO Technology (Shanghai). Briefly, after 48 hours of transfection, the 293T cells were collected and assayed for luciferase activity using an Enzygnost instrument (Spark 10M, TECAN). The results were normalized to the ratio between firefly activity and renilla luciferase activity. Results were analyzed from three independent experiments and each experiment was performed in sextuplicate.

BrdU Injection and Immunofluorescence Staining

BrdU (5-bromo-2'-deoxyuridine, Sigma) was administered via an intraperitoneal injection (50 mg/kg) for five days at both the 2nd week after virus injection, twice every day at 8 h intervals. BrdU was dissolved in normal saline (0.9%, pH 7.4) and maintained in the dark to protect it from light. Coronal sections of the hippocampus (30 µm) were collected from each brain. For BrdU staining, tissue sections were pretreated with 1M HCl for 30 min at 45°C, then washed 3 times with PBS before primary antibody incubation. Primary antibodies were anti-BrdU (1:100, Bioworld Technology), anti-doublecortin (anti-DCX) (1:200, Cell Signaling Technology) and

anti-NeuN (1:500, Cell Signaling Technology). Secondary antibodies were Alexa Fluor 488 or 546 conjugated (1:500, Abcam). Fluorescence images were acquired with use of confocal microscopy (LSM880; Zeiss).

Immunofluorescence

Rats were anesthetized with sodium phenobarbital (30 mg/kg) using an intraperitoneal injection and perfused with 4% PFA through the heart. Brains were removed and fixed in 4% PFA overnight, then transferred to 30% sucrose solution for two days. Frozen coronal sections of the hippocampus were cut with a thickness of 30um and stored at -20 °C. The sections were incubated overnight at 4 °C with primary antibodies. Primary antibodies used were anti-Sox2 (1:100; Bioworld), anti-doublecortin (anti-DCX) (1:200, Cell Signaling Technology), anti-Nestin (1:20, Thermo Fisher) and anti-NeuN (1:1000, Abcam). Secondary antibodies were alexa-405 (1:1000, Abcam) and alexa-568 (1:1000, Invitrogen). Fluorescence images were obtained with use of confocal microscopy (LSM880; Zeiss) and processed by ZEN software.

For immunofluorescence staining of cells, the cells were fixed in 4%PFA for 15min, followed by treatment with 3%BSA for 1h at room temperature. They were then incubated overnight at 4 °C with primary antibodies, and then incubated with secondary antibodies for 1 h at room temperature after 24h. Fluorescence images were acquired with use of confocal microscopy (Dragonfly 200; Andor).

Western blotting

Protein was isolated from rat tissue by homogenization with lysis buffer containing protease and phosphatase inhibitors. Protein samples (20ug) were fractionated on SDS-PAGE gels by electrophoresis and then transferred onto PVDF membranes. Membranes were incubated with 5% non-fat milk for 1 h at room temperature and overnight with primary antibodies at 4 °C. Primary antibodies were anti-CDKL5 (1:500, Abcam), anti-KLF4 (1:1000, Abcam) and anti-GAPDH (1:4000, Proteintech). Secondary antibodies were anti-HRP antibodies (1:5000, Bioworld). Bands on the membranes were detected with use of the Enhanced Chemiluminescence kit (ECL, Thermo Fisher) and quantified using Image-J software. The primary antibody GAPDH was used as a loading control.

RNA preparation and Quantitative real-time PCR

Total RNA of exosomes, CSF, cells and tissues were isolated using the miRNeasy Micro Kit (QIAGEN 217084) according to the manufacturer's protocol. RNA purity and concentration were determined with use of a Nano Drop ND-1000 spectrophotometer (Nano Drop Thermo, Wilmington, DE). Expression levels of miRNA were determined with use of quantitative real-time RT-PCR. The All-in-One™ miRNA qRT-PCR Detection Kit (GeneCopoeia, QP018, USA), the HiScript II 1st Strand cDNA Synthesis Kit (Vazyme, Nanjing) and ChamQ SYBR Qpcr Master Mix (Vazyme, Nanjing) were used to quantify expression levels of circRNA by the Bio-Rad IQ5 Real Time PCR System. Bio-rad's IQ5 Software was used to analyze the PCR reaction data and the sequences of primers are listed in Supplementary Table 3.

Hippocampus Slices Preparation and Electrophysiological Recordings

Slices were cutting in cutting solution (pH 7.40) containing (in mM) 119 choline chloride, 30 Glucose, 26 NaHCO₃, 7 MgSO₄, 2.5 KCl, 1 NaH₂PO₄, 1 CaCl₂, 3 sodiumpyruvate, 1.3 sodium L-ascorbate and 1 kynurenicacid. Then, slices were transferred as quickly as possible to a recovery solution containing. (in mM) 85 NaCl, 24 NaHCO₃, 4 MgCl₂, 2.5 KCl, 1.25 NaH₂PO₄, 0.5 CaCl₂, 25 glucoses and 50 sucrose to recover for 30 min at 30 °C. The glass micropipettes (4–6 MΩ) were filled with an internal solution containing (in mM) 130 CsMeSO₄, 10 CsCl, 4 NaCl, 1 MgCl₂, 5 MgATP, 5 EGTA, 10 HEPES, 0.5 Na₃GTP, 10 phosphocreatine and 4 QX-314, with a pH of 7.35. During recordings, slices were continuously perfused with an artificial cerebral spinal fluid (ACSF) contained (in mM) 120 NaCl, 3.5 KCl, 2.5 CaCl₂, 1.3 MgSO₄, 1.25 NaH₂PO₄, 26 NaHCO₃ and 10 glucoses.

Reference:

- 1 Li, K., Zhou, T., Liao, L. J., Yang, Z. F., Wong, C., Henn, F., Malinow, R., Yates, J. R. & Hu, H. L. (2013). beta CaMKII in Lateral Habenula Mediates Core Symptoms of Depression. *Science*. 341, 1016-1020.
- 2 Liu, L. & Duff, K. (2008). A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. *J Vis Exp*.
- 3 Linker, K. E., Elabd, M. G., Tawadrous, P., Cano, M., Green, K. N., Wood, M. A. & Leslie, F. M. (2020). Microglial activation increases cocaine self-administration following adolescent nicotine exposure. *Nat Commun*. 11.
- 4 Mao, Z. F., Ouyang, S. H., Zhang, Q. Y., Wu, Y. P., Wang, G. E., Tu, L. F., Luo, Z., Li, W. X., Kurihara, H., Li, Y. F. et al. (2020). New insights into the effects

- of caffeine on adult hippocampal neurogenesis in stressed mice: Inhibition of
CORT-induced microglia activation. *Faseb J.* 34, 10998-11014.
- 5 Woodbury, M. E., Freilich, R. W., Cheng, C. J., Asai, H., Ikezu, S., Boucher, J.
D., Slack, F. & Ikezu, T. (2015). miR-155 Is Essential for Inflammation-
Induced Hippocampal Neurogenic Dysfunction. *J Neurosci.* 35, 9764-9781.
- 6 Tamashiro, T. T., Dalgard, C. L. & Byrnes, K. R. (2012). Primary Microglia
Isolation from Mixed Glial Cell Cultures of Neonatal Rat Brain Tissue. *Jove-J
Vis Exp.*
- 7 Witting, A. & Moller, T. (2011). Microglia cell culture: a primer for the novice.
Methods Mol Biol. 758, 49-66.
- 8 Seibenhener, M. L. & Wooten, M. W. (2012). Isolation and Culture of
Hippocampal Neurons from Prenatal Mice. *Jove-J Vis Exp.*
- 9 Mao, L. M. & Wang, J. Q. (2001). Upregulation of preprodynorphin and
preproenkephalin mRNA expression by selective activation of group I
metabotropic glutamate receptors in characterized primary cultures of rat
striatal neurons. *Mol Brain Res.* 86, 125-137.
- 10 Huang, S., Ge, X. T., Yu, J. W., Han, Z. L., Yin, Z. Y., Li, Y., Chen, F. L., Wang,
H. C., Zhang, J. N. & Lei, P. (2018). Increased miR-124-3p in microglial
exosomes following traumatic brain injury inhibits neuronal inflammation and
contributes to neurite outgrowth via their transfer into neurons. *Faseb J.* 32,
512-528.
- 11 Jiang, N., Xiang, L. S., He, L., Yang, G. D., Zhen, J. X., Wang, C. L., Zhang, Y.

- M., Wang, S. N., Zhou, Y., Sheu, T. J. et al. (2017). Exosomes Mediate Epithelium-Mesenchyme Crosstalk in Organ Development. *Acs Nano*. 11, 7736-7746.
- 12 Czupalla, C. J., Yousef, H., Wyss-Coray, T. & Butcher, E. C. (2018). Collagenase-based Single Cell Isolation of Primary Murine Brain Endothelial Cells Using Flow Cytometry. *Bio-Protocol*. 8.
- 13 Estevez, F. J. M., Mathews, T. D., Biffi, A. & Peviani, M. (2019). Simultaneous Flow Cytometric Characterization of Multiple Cell Types Retrieved from Mouse Brain/Spinal Cord Through Different Homogenization Methods. *Jove-J Vis Exp*.
- 14 Li, Y., He, X. L., Kawaguchi, R., Zhang, Y., Wang, Q., Monavarfeshani, A., Yang, Z. Y., Chen, B., Shi, Z. J., Meng, H. Y. et al. (2020). Microglia-organized scar-free spinal cord repair in neonatal mice. *Nature*. 587, 613-+.
- 15 Marques-Garcia, F. & Isidoro-Garcia, M. (2016). Protocols for Exosome Isolation and RNA Profiling. *Methods Mol Biol*. 1434, 153-167.